Galectin Therapeutics (NASDAQ: GALT) and Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitabiliy, institutional ownership, dividends, valuation and risk.
Analyst Ratings
This is a breakdown of recent ratings for Galectin Therapeutics and Biohaven Pharmaceutical Holding Co, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Galectin Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Biohaven Pharmaceutical Holding Co | 0 | 0 | 5 | 0 | 3.00 |
Galectin Therapeutics presently has a consensus price target of $2.08, suggesting a potential downside of 4.43%. Biohaven Pharmaceutical Holding Co has a consensus price target of $31.75, suggesting a potential upside of 27.61%. Given Biohaven Pharmaceutical Holding Co’s stronger consensus rating and higher possible upside, analysts plainly believe Biohaven Pharmaceutical Holding Co is more favorable than Galectin Therapeutics.
Earnings & Valuation
This table compares Galectin Therapeutics and Biohaven Pharmaceutical Holding Co’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Galectin Therapeutics | N/A | N/A | -$20.48 million | ($0.67) | -3.25 |
| Biohaven Pharmaceutical Holding Co | N/A | N/A | -$72.14 million | N/A | N/A |
Profitability
This table compares Galectin Therapeutics and Biohaven Pharmaceutical Holding Co’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Galectin Therapeutics | N/A | -546.35% | -122.08% |
| Biohaven Pharmaceutical Holding Co | N/A | N/A | -172.50% |
Insider & Institutional Ownership
11.4% of Galectin Therapeutics shares are owned by institutional investors. 40.3% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
About Biohaven Pharmaceutical Holding Co
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
